Holen Sie sich die Stockscreener-App
1.01
2.88%
-0.03
Handel nachbörslich:
1.06
0.05
+4.95%
Schlusskurs vom Vortag:
$1.04
Offen:
$1.05
24-Stunden-Volumen:
325.62K
Relative Volume:
0.87
Marktkapitalisierung:
$81.46M
Einnahmen:
$3.91M
Nettoeinkommen (Verlust:
$-206.53M
KGV:
-0.2654
EPS:
-3.8057
Netto-Cashflow:
$-167.78M
1W Leistung:
-8.18%
1M Leistung:
-31.76%
6M Leistung:
-42.29%
1J Leistung:
-38.79%
1-Tages-Spanne:
$1.00
$1.08
1-Wochen-Bereich:
$1.00
$1.13
52-Wochen-Spanne:
$0.99
$2.5362
I Mab Adr Stock (IMAB) Company Profile
Vergleichen Sie IMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IMAB | 1.01 | 81.46M | 3.91M | -206.53M | -167.78M | -3.8057 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-09 | Eingeleitet | Siebert Williams Shank | Buy |
| 2021-06-02 | Eingeleitet | Daiwa Securities | Buy |
| 2021-03-15 | Eingeleitet | Needham | Buy |
| 2021-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-25 | Eingeleitet | Piper Sandler | Overweight |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-12 | Eingeleitet | China Renaissance | Buy |
| 2020-02-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
I Mab Adr Aktie (IMAB) Neueste Nachrichten
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - TipRanks
I-Mab names Sean Fu as new CEO - Investing.com India
I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register
Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register
If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register
Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register
Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register
Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register
Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register
Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register
Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register
Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News
Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex
I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com
Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com
I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News
There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News
Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India
I-Mab appoints new chairman and interim CEO - Investing.com
2024-07-15 | I-Mab Announces Leadership Transitions | NDAQ:IMAB | Press Release - Stockhouse Publishing
Financial Health Report: I-Mab ADR (IMAB)'s Ratios Tell a Tale – DWinneX - The Dwinnex
Teva Acquires Rights to Oncology Biosimilar Candidates - Yahoo News UK
It is Poised to be a Bull Market for I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab names new Chief Medical Officer to enhance oncology pipeline - Investing.com India
I-Mab names new Chief Medical Officer to enhance oncology pipeline By Investing.com - Investing.com
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Analysts review I-Mab ADR's rating – Knox Daily - Knox Daily
I-Mab and Bristol Myers team up for cancer drug trial By Investing.com - Investing.com
Watch this stock's price performance: I-Mab ADR (NASDAQ:IMAB) – US Post News - US Post News
I-Mab ADR Inc. (IMAB) Price Performance: A Technical Analysis Perspective - The InvestChronicle
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Check out these key findings about I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - GlobeNewswire Inc.
AbbVie Partners With Chinese Biotech for Cancer Candidate - Yahoo News NZ
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Lifestyle UK
Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate ProtectionTipRanks.com - TipRanks
I-Mab Announces CMO Transition, Interim Successor NamedTipRanks.com - TipRanks
I-Mab Finalizes Divestiture and Resolves ObligationsTipRanks.com - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com
Finanzdaten der I Mab Adr-Aktie (IMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):